Skip to main content
News

Tech Opportunity Webinar: “New Gene Therapy Method for Treating CRX-autosomal Dominant Leber Congenital Amaurosis (LCA)”

By November 1, 2022No Comments

Cursor and Re NCI Tech Opportunity Webinar New Gene Therapy Method for Treating CRX autosomal Dominant Leber Congenital Amaurosis LCA 11 15 11am ET US jtk delmarvagroup com Delmarva Group LLC MailAn NCI Technology Opportunity Webinar

We invite you to register and join us on November 15 from 11:00 am – 12:00 pm ET for a free NCI technology webinar.

Attendees will hear from Drs. Anand Swaroop, Ph.D. and Kamil Kruczek, Ph.D. of the National Eye Institute about a new gene therapy method for treating CRX-autosomal dominant Leber Congenital Amaurosis (LCA). LCA is a rare genetic disease that is responsible for about 20% of all childhood blindness. It’s caused by mutations in any of at least 25 genes that control photoreceptor development or function. LCA has both recessive and dominant forms. Currently, there is an FDA approved gene therapy for treating only one of the recessive forms of LCA caused by mutations in the RPE65 gene. In addition to most recessive forms, the dominant form of LCA with underlying mutations in CRX remains untreatable.

Click here to register or learn more.

Leave a Reply

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.